Lys-[Des-Arg9]Bradykinin TFA |
| カタログ番号GC61535 |
Lys-[Des-Arg9]Bradykinin TFA は、天然に存在するキニンであり、強力で選択性の高いブラジキニン B1 受容体アゴニストであり、Ki は、ヒト、マウス、ウサギの B1 受容体に対してそれぞれ 0.12 nM、1.7 nM、0.23 nM です。
Products are for research use only. Not for human use. We do not sell to patients.
![Lys-[Des-Arg9]Bradykinin TFA 化学構造](/media/struct/GC6/GC61535.png "Lys-[Des-Arg9]Bradykinin TFA 化学構造")
Cas No.: 2763588-90-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lys-[Des-Arg9]Bradykinin TFA, a naturally occurring kinin, is a potent and highly selective bradykinin B1 receptor agonist with a Ki of 0.12 nM, 1.7 nM and 0.23 nM for human, mouse and rabbit B1 receptors, respectively. Lys-[Des-Arg9]Bradykinin TFA has low inhibitory activity on B2 receptors[1][2].
Lys-[Des-Arg9]Bradykinin is formed by the proteolytic cleavage of bradykinin, exerts its effects through bradykinin B1 receptor (B1R)[1].Lys-[Des-Arg9]Bradykinin (Lda-BK; 10 μM) enhances the secretion of IL-12p70 and inhibits the secretion of IL-12p40 by mature hMo-DCs. Pretreatment with Lys-[Des-Arg9]Bradykinin treatment reduces the migration of mature hMo-DCs toward medium alone, suggesting that Lys-[Des-Arg9]Bradykinin may inhibit the chemokinesis of mature hMo-DCs[1].
Lys-[Des-Arg9]Bradykinin (1 μg; intra-artenal injection; New Zealand White rabbits) treatment reduces peripheral vascular resistance in LPS-induced rabbits, but the effect is brief (T1/2 is 118-195 s)[3].
[1]. Rosalind Gulliver, et al. Lys-des[Arg9]-bradykinin alters migration and production of interleukin-12 in monocyte-derived dendritic cells. Am J Respir Cell Mol Biol. 2011 Sep;45(3):542-9. [2]. L M Fredrik Leeb-Lundberg, et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005 Mar;57(1):27-77. [3]. G Drapeau, et al. Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. J Pharmacol Exp Ther. 1991 Dec;259(3):997-1003.
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *